Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01320865|
Recruitment Status : Withdrawn
First Posted : March 23, 2011
Last Update Posted : February 4, 2014
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
|Subjects with PAH treated with nilotinib|
- Measuring circulating markers of Nilotinib affect [ Time Frame: within one year of the end of the study ]We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib.
- Evaluate effect of Nilotinib on the activation of mast cells. [ Time Frame: within one year of the end of the study ]We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib. We will also look at the proliferation of mast cell progenitors and correlate this to clinical markers used to monitor this disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01320865
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Kewal Asosingh, Ph.D||The Cleveland Clinic|